Gabriel Gómez

Virgo Ventures is a Swiss advisory firm in venture capital, based in the Lausanne area. Virgo collaborates with private and institutional investors, as well as philanthropic ventures, for their startup investments. Additionally, Virgo assists startup entrepreneurs in their corporate development activities and has served as the advisor to Initiative Capital Romandie, a local fund supporting startups in the French-speaking part of Switzerland

Foundation for Innovation in Technology (FIT) helps start-ups since 1994. It aims to support technological and innovative projects, offer financial aid and coaching as long as projects have a good chance of technical and economic feasibility and done in collaboration with one of the High Schools of Switzerland (ETH, universities, HES).

Aleva Neurotherapeutics develops the next generation of implantable electrodes for brain neuromodulation, based on a MEMS technology. The first application will be in Deep Brain Stimulation (DBS) for indications such as Parkinson's Disease and Essential Tremor. Alevaʼs microDBS Technology can significantly reduce the overall cost of a DBS procedure while nearly eliminating the complications and side effects associated with the therapy.

Anergis is a clinical-stage biopharmaceutical company based in Switzerland. Anergis discovers and develops proprietary synthetic allergy vaccines with the aim to provide allergy patients and doctors with a significantly improved treatment option: ultra-fast desensitization.

Alpana Ventures is a Swiss early stage VC firm built for entrepreneurs by entrepreneurs. Our investment model bridges Swiss & European startups to the Silicon Valley and Asia, with a focus on exit strategies in the US and Asia.

Venture Capital investment management. Fund management, investment analysis, due diligence and follow-up (Board of Directors presence) of high-tech start-up companies with high growth potential in life sciences, industrial projects and materials. Private Equity fund of funds management and advisory for a local bank (member of one of the funds’ investment committee)

MyoPowers Medical Technologies is a Swiss medical device company that has developed a unique and proprietary artificial muscle technology to restore or improve muscle function. MyoPowers is currently developing implantable medical devices for the treatment of stress urinary incontinence.

Diagnoplex’s lead product, Colox®, is a convenient and minimally-invasive blood test developed for the systematic screening of colorectal cancer. The gene signature underlying Colox® has been designed to detect early and advanced disease stages with outstanding results and reliability. In 2014, the company was sold in a MBO.

Viroblock’s mission is to fight pathogenic viral infections by developing and commercializing a series of consumer healthcare products. Viroblock’s patented antiviral technology is uniquely placed to deliver topical anti-viral products against all types of enveloped viruses.

Through its leading-edge new micro-machining process, the Electrothermal Focusing technology, picoDrill specializes in the development of unique proprietary processes to improve cost effective micro-machining techniques on wide range of materials. These include glass, ceramic, silica, sapphire and other semi or non conducting substrates. In 2010, the company was sold to Asahi Glass Co.